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ABSTRACT
Background: Co-occurrence of posttraumatic stress disorder (PTSD) in psychosis (estimated
as 12%) raises personal suffering and societal costs. Health–economic studies on PTSD
treatments in patients with a diagnosis of a psychotic disorder have not yet been con-
ducted, but are needed for guideline development and implementation. This study aims to
analyse the cost-effectiveness of guideline PTSD therapies in patients with a psychotic
disorder.
Methods: This health–economic evaluation alongside a randomized controlled trial included
155 patients with a psychotic disorder in care as usual (CAU), with comorbid PTSD.
Participants received eye movement desensitization and reprocessing (EMDR) (n = 55),
prolonged exposure (PE) (n = 53) or waiting list (WL) (n = 47) with masked assessments at
baseline (T0) and at the two-month (post-treatment, T2) and six-month follow-up (T6). Costs
were calculated using the TiC-P interview for assessing healthcare consumption and pro-
ductivity losses. Incremental cost-effectiveness ratios and economic acceptability were
calculated for quality-adjusted life years (EQ-5D-3L-based QALYs) and PTSD ‘Loss of diag-
nosis’ (LoD, CAPS).
Results: Compared to WL, costs were lower in EMDR (-€1410) and PE (-€501) per patient per
six months. In addition, EMDR (robust SE 0.024, t = 2.14, p = .035) and PE (robust SE 0.024,
t = 2.14, p = .035) yielded a 0.052 and 0.051 incremental QALY gain, respectively, as well as
26% greater probability for LoD following EMDR (robust SE = 0.096, z = 2.66, p = .008) and
22% following PE (robust SE 0.098, z = 2.28, p = .023). Acceptability curves indicate high
probabilities of PTSD treatments being the better economic choice. Sensitivity analyses
corroborated these outcomes.
Conclusion: Adding PTSD treatment to CAU for individuals with psychosis and PTSD seem
to yield better health and less PTSD at lower costs, which argues for implementation.
Beneficios en la economía de la salud del tratamiento del trauma en
psicosis
Antecedentes: La comorbilidad de TEPT en la psicosis (estimada en 12%) aumenta el
sufrimiento personal y los costos para la sociedad. No se han realizado aún estudios de
economía de la salud de los tratamientos de TEPT en pacientes con diagnóstico de un
trastorno psicótico, pero son necesarios para el desarrollo e implementación de guías. Este
estudio apunta a analizar la costo-efectividad de las terapias para TEPT con guías clínicas en
pacientes con un trastorno psicótico.
Métodos: Esta evaluación de economía de la salud asociada a un estudio randomizado
controlado incluyó a 155 pacientes con un trastorno psicótico en cuidado habitual (CAU),
con TEPT comórbido.
Los pacientes recibieron terapia de reprocesamiento por movimientos oculares (EMDR,
n=55), exposición prolongada (PE, n=53) o lista de espera (WL, n=47) con evaluaciones
ciegas basal (T0), a los 2 meses (post-tratamiento, T2) y a los 6 meses de seguimiento (T6).
Los costos fueron calculados usando la entrevista TiC-P para evaluar el consumo en los
sistemas de salud y pérdidas de productividad. Las tasas incrementales de costo-efectividad
y acepabilidad económica fueron calculadas por Años de Vida ajustados por calidad (QALY
basado en EQ-5D-3L) y pérdida de diagnóstico de TEPT (LoD, CAPS)
Resultados: En comparación a lista de espera, los costos fueron menores en EMDR (-€1410)
y PE (-€501) por paciente por cada 6 meses. Además, EMDR (SE robusta 0.024, t=2.14,
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p=0.035) y PE (SE robusta 0.024, t=2.14, p=0.035) produjeron una ganancia incremental en
QALY de 0.05 y una probabilidad 26% mayor de LoD luego de EMDR (SE robusta 0.096,
z=2.66, p=0.008) y 22% luego de PE (SE robusta 0.098, z=2.28, p=0.023). Las curvas de
aceptabilidad indican altas probabilidades de que los tratamientos para TEPT sean la mejor
alternativa económica. Los análisis de sensibilidad corroboraron estos resultados.
Conclusion: El agregar tratamiento para TEPT a los cuidados habituales en pacientes con
psicosis y TEPT parece producir mejor salud y menos TEPT a menor costo, lo que aboga por
su implementación.
治疗精神病症（psychosis）中的创伤的健康-经济收益分析
背景：PTSD在精神病症中的共病率（估计为12％）会增加个人痛苦和社会成本。尚未对
PTSD治疗在精神病症的患者中展开健康-经济研究（health–economic studies），但这些
研究是治疗指南制定和实施所必需的。本研究旨在分析精神失常（psychotic disorder）患
者的PTSD治疗指南的成本-效益。
方法：这项健康-经济评估与一项随机对照试验一起进行，包括155名 接受普通护理(CAU)
的共病PTSD的精神失常患者。被试接受了眼动脱敏和再处理疗法（EMDR，n= 55），延
长暴露疗法（PE，n= 53）或进入等待名单（WL，n= 47），并在基线期（T0）和2个月
(治疗后，T2)和6个月（T6）的随访进行了隐蔽评估（masked assessments）。使用TiC-P
访谈评估医疗保健消耗和生产力损失。根据质量调整生命时间（quality-adjusted life
years，基于EQ-5D-3L的QALYs）和PTSD’去诊断’（LoD，CAPS）计算增量成本效益比和经
济可接受性。
结果：与WL相比，每位患者的EMDR（ −1410欧元）和PE（ −501欧元）每六个月治疗成
本较低。此外，EMDR（robust SE 0.024，t = 2.14，p = .035）和PE（robust SE 0.024，t
= 2.14，p = .035）产生0.05增量的QALY增益，EMDR后的LoD概率增加26％（robust SE =
0.096，z = 2.66，p = .008）和PE后增加22％（robust SE 0.098，z = 2.28，p = .023）。可
接受性曲线表明 PTSD治疗的高概率是更经济的选择。敏感性分析证实了这些结果。
结论：在同时患有精神病症和创伤后应激障碍的个体的CAU加入PTSD治疗似乎可以以更
低的成本得到更好的健康和更少的 PTSD，从而有助于实践运用。
Until now, no study has assessed the cost-effectiveness
of trauma-focused treatment (TFT) in patients with
a psychotic disorder. This is probably related to existing
controversies as to whether or not to offer TFT to this
target group, e.g. for a comorbid posttraumatic stress
disorder (PTSD). On the one hand, manuals (Foa,
Hembree, & Rothbaum, 2007), guidelines (Cloitre,
Courtois, & Ford et al., 2012), clinicians (Becker,
Zayfert, & Anderson, 2004; Frueh, Cusack, Grubaugh,
Sauvageot, &Wells, 2006; Meyer, Farrell, Kemp, Blakey,
& Deacon, 2014; Salyers, Evans, Bond, & Meyer, 2004;
van Minnen, Hendriks, & Olff, 2010) and researchers
(Ronconi, Shiner, &Watts, 2014) generally apply exclu-
sion or a stabilization programme instead of offering
TFT for psychotic individuals. On the other hand, there
is no evidence to suggest that TFT would be unsafe and
detrimental for individuals with comorbid problems
such as psychosis (Brand, McEnery, Rossell, Bendall,
& Thomas, 2017; van Minnen et al., 2010). On the
contrary, evidence suggests that first-line TFT, more
specifically prolonged exposure (PE) and eye move-
ment desensitization and reprocessing (EMDR) ther-
apy, might be as effective in patients with a psychotic
disorder as in other patient groups (Brand et al., 2017;
De Jongh et al., 2016). This controversy affects many
people. It is estimated that in Europe about 600,000 and
in the USA a quarter of a million adults need treatment
for both a psychotic disorder and a comorbid PTSD
(Achim et al., 2011). Yet, given the practice of exclusion,
very few individuals will have received TFT. Resolving
the PTSD treatment controversy is not only important
for patients, but also for their families and the larger
community because, worldwide, psychosis (Murray
et al., 2012; Neil, Carr, Mihalopoulos, Mackinnon, &
Morgan, 2014b; Reininghaus et al., 2015) and PTSD
(Beard, Weisberg, & Keller, 2010; Issakidis, Sanderson,
Corry, Andrews, & Lapsley, 2004) are among the most
personally disabling and economically costly disorders.
The joint impact of both disorders worsens the course
of the disease and further increases costs (Lysaker &
LaRocco, 2008; Seow et al., 2016). The need to address
costs and effects of PTSD treatment in psychosis is
reported as one of the NICE 2014 key priorities for
implementation in recent clinical guidelines, sparking
the awareness and assessment of trauma and PTSD in
psychosis (NICE, 2014). The 2017 APA PTSD guideline
(APA, 2017) and the 2013 WHO Guidelines for the
Management of Conditions Specifically Related to
Stress (WHO, 2013) state the importance of cost-
effectiveness studies to expand the evidence base for
future guideline recommendations. Guideline panels
and financiers need cost-effectiveness examinations in
order to be able to decide on the application, dissemi-
nation and implementation of TFT for individuals with
psychotic disorders. Importantly, no economic data are
currently available on this topic.
Cognitive behavioural therapy (CBT) has favour-
able economic evaluations for anxiety disorders
(Issakidis et al., 2004; Mihalopoulos, Baxter,
Whiteford, & Vos, 2014) and PTSD (Mihalopoulos
et al., 2015), but was not examined in psychotic PTSD
populations. A study among US veterans (N = 60)
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showed that PE for PTSD led to a significant and
strong reduction in symptomatology and PE reduced
health service utilization by (on average) US$194 per
person (Tuerk et al., 2013). A randomized controlled
trial in a non-psychotic traumatized population (N
= 103) showed PE to be cost-effective relative to
sertraline, saving US$262 per individual and yielding
a 0.056 incremental gain in quality-adjusted life years
(QALY) (Le, Doctor, Zoellner, & Feeny, 2014). PE
was considered to be the preferable treatment option.
Although EMDR is a recommended treatment for the
effects of exposure to traumatic events, it has not yet
produced a cost-effectiveness study in any patient
group.
The present study conducts a cost-effectiveness ana-
lysis alongside a randomized clinical trial. In that trial
we challenged the no-TFT paradigm in psychosis by
demonstrating that TFT for PTSD primarily reduced
PTSD (van Den Berg et al., 2015b) and secondarily
also paranoid thinking (de Bont et al., 2016), depres-
sion (in PE) (de Bont et al., 2016) and re-victimization
risk (van Den Berg et al., 2015a). Additionally, TFT
fostered remission from schizophrenia and had no
detrimental effect on voice hearing and social func-
tioning (de Bont et al., 2016). The present health–
economic analysis addresses the question as to
whether PTSD treatment in patients with a psychotic
disorder is economically affordable and perhaps even
cost-saving. The study assesses costs and effects in 155
patients in care as usual (CAU) for psychosis, compar-
ing a PTSD waiting list (WL) to add-on first-line
PTSD treatments, i.e. EMDR therapy and PE therapy.
1. Methods
1.1. Participants and procedures
Full details of the study are reported elsewhere (de
Bont et al., 2013; van Den Berg et al., 2015b). In brief,
the study was designed as a randomized controlled
trial in three parallel groups (EMDR, PE, WL) mea-
suring costs and effects at baseline (T0), at the two-
month (post-treatment, T2) and six-month follow-up
(T6). Only the experimental conditions (EMDR and
PE) had a longer-term follow-up, conducted at
12 months post-baseline, including measurements of
both effects and costs, in order to assess the develop-
ment (the robustness) of both outcomes over time.
Participants were recruited from 13 mental health
services in the Netherlands. Eligible were adults (18–-
65 years) in care for psychotic disorders or mood
disorders with psychotic features as confirmed by the
Mini-International Neuropsychiatric Interview Plus
(MINI Plus) (Sheehan et al., 1998) and suffering from
co-morbid PTSD as established with the Clinician
Administered PTSD Scale (CAPS) (Blake et al., 1995).
Exclusion criteria were (i) language or attendance
problems, (ii) seclusion, (iii) staying in a closed ward,
(iv) high suicidality (MINI-Plus ‘high’ suicidality + last
suicide attempt < six months + BDI-II-score ≥ 35), (v)
mood and/or antipsychotic medication changes two
months prior to study start, and (vi) IQ < 70. All
eligible participants received a study description and
155 individuals gave written consent to participate. The
CONSORT flow chart is available online
(Supplemental Figure 1). The independent randomiza-
tion bureau of the Parnassia Psychiatric Institute ran-
domized participants using www.randomizer.org,
yielding N = 47 participants in WL, N = 55 in EMDR
and N = 53 in PE. Assessors masked for the partici-
pants’ randomization status carried out the measure-
ments. The trial (de Bont et al., 2013) was designed in
accordance with CONSORT guidelines, registered at
isrctn.com (ISRCTN79584912) and approved by the
Medical Ethics committee of the VU University
Medical Center.
1.2. Interventions
All 155 participants received standard care from
Multidisciplinary Assertive Community Treatment
teams, consisting of pharmaceutical intervention,
psychological treatment, casework, nursing and/or
coaching (e.g. individual placement and support).
Trauma-focused interventions were not allowed in
CAU. As fully described elsewhere (de Bont et al.,
2013; van Den Berg et al., 2015b), the waiting list
patients obtained information on PTSD from their
therapists. After six months they could choose the
PTSD treatment they desired. Patients in the
experimental conditions received eight weekly ses-
sions of EMDR or PE therapy, yielding good to
excellent adherence and therapist competence.
EMDR was provided in 90-minute sessions con-
ducted according to the standard 8-phase EMDR
protocol using the Dutch translation. Eye move-
ments were applied to tax patients’ working mem-
ory. EMDR therapy did not contain homework
assignments. PE consisted of 90-minute imaginal
exposure sessions in which the patient recounted
the most disturbing traumatic memories. Between
the sessions, patients listened daily to the audio-
recording of the weekly sessions and completed
exposure in vivo assignments, during which fearful
trauma-related situations were approached.
1.3. Measures
The health outcome was QALY based on the EuroQol
(EQ-5D-3L) self-report (König, Roick, & Angermeyer,
2007) which measured health-related quality of life in
five dimensions: mobility, self-care, usual activities, pain/
discomfort and anxiety/depression. The five dimensions
have three scoring levels (no problem, some problem,
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severe problem) describing 243 health states. The pre-
ference for each health state is expressed in utilities.
A utility is anchored at 1 (perfect health) and 0 (death).
We based utilities on a survey in the Netherlands
(Lamers, Stalmeier, McDonnell, Krabbe, & van
Busschbach, 2005) and used the so-called ‘Dutch tariff’.
Utilities were obtained at baseline (T0), post-treatment
(T2) and at six months (T6). Changes in utilities over
time were converted to QALYs with the area under the
curve method (Matthews, Altman, Campbell, &
Royston, 1990). The EQ-5D has good reliability and
validity (König et al., 2007).
The clinical outcome was ’loss of PTSD diagnosis’
(LoD), measured with the Clinician-Administered
PTSD Scale (CAPS-IV). The CAPS (Blake et al.,
1995) demonstrates excellent reliability, validity and
sensitivity (Weathers, Keane, & Davidson, 2001). The
CAPS is considered to be the gold standard for diag-
nosing DSM-IV-TR (APA, 2000) PTSD presence
(y/n) and symptom severity (0–136). Following
PTSD benchmark guidelines (Schnurr & Lunney,
2016), we defined LoD as no longer fulfilling the
criteria of a CAPS-PTSD diagnosis and a CAPS sever-
ity score < 45. LoD was measured at six-months
follow-up in all conditions, and at 12-months follow-
up only in the PE and EMDR conditions.
1.4. Costs
Costs were assessed using the Trimbos/iMTA ques-
tionnaire for Costs associated with Psychiatric Illness,
TiC-P (Hakkaart-van Roijen, 2002) developed by
Trimbos institute and the Institute for Medical
Technology Assessment (MTA). The TiC-P interview
asks individuals for ‘health care units’ (see Table 1),
i.e. the number of contacts with healthcare providers
(e.g. ‘family doctor/GP’) and for productivity losses
stemming from absenteeism and/or presenteeism, i.e.
being less productive while at work or at home.
Healthcare costs (including intervention costs of the
add-on experimental treatments) were calculated by
multiplying health care units by the standard full eco-
nomic unit cost price in 2014 Euro (Supplementary
Table 1). Medication costs were calculated by multi-
plying the official Dutch costs of Daily Defined
Dosages (DDD) (http://www.medicijnkosten.nl) by
the number of prescription days, plus €6.00 for the
pharmacist’s dispensing costs.
Costs of productivity losses. Productivity losses stem-
ming from absenteeism and presenteeism were calcu-
lated according to the human capital approach (Rice &
Cooper, 1967) using standard hourly productivity
costs (Hakkaart-van Rooijen, Tan, & Bouwmans,
2010). The cost accumulation from baseline to six
months was assessed with the area under the curve
method (Matthews et al., 1990).
Societal costs are the sum of healthcare costs and
productivity losses: the total amount that is imposed
upon society to pay as a consequence of the disorder.
The TiC-P is a reliable and valid alternative for
collecting data on care consumption and productivity
losses (Bouwmans et al., 2013). Costs were measured
in Euro (€) for the reference year 2014.
1.5. Analysis
The cost-effectiveness analyses were conducted in
accordance with the CONSORT (http://www.consort-
statement.org/) and CHEERS (Husereau et al., 2013)
guidelines. The aim of the cost-utility study (CUA) is
to obtain incremental cost-utility ratios (ICURs) of
costs per QALY gained. The aim of the cost-
effectiveness study (CEA) is to obtain cost-
effectiveness ratios (ICERs) of costs per lost PTSD
diagnosis (LoD). Missing values of LoD, QALYs and
costs at follow-up were imputed using the expectation
maximization (EM) algorithm as implemented in
SPSS 22.0. In a linear probability model, the incre-
mental effects on QALY health gains and LoD clinical
improvement were examined using robust standard
errors based on the first-order Taylor-series lineariza-
tion method.
An ICER (or ICUR) summarizes cost-effectiveness
of a healthcare intervention. ICERs are calculated as
(C1 − C0)/(E1 − E0) where C1 and E1 are the cost and
effect in an experimental condition (i.e. EMDR or
PE) and C0 and E0 are the cost and effect in the
control condition (WL). In Stata14.2 resampling pro-
cedures (bootstrapping) generated 2500 ICERs, with
incremental costs and incremental effects under
a seemingly unrelated regression equations (SURE)
model adjusted for possibly confounding baseline
differences between the conditions. The simulated
ICERs were depicted as a scatter over a cost-
effectiveness plane: the intersection (zero) represents
WL, the vertical axis represents the incremental costs
of the treatment condition compared to WL and the
horizontal axis represents the incremental effects of
the treatment compared to WL. When most ICERs
fall in the top left quadrant of the plane (Q2), depict-
ing less effect at higher costs of the treatment com-
pared to WL, then the treatment is considered
‘inferior’ to WL and is consequentially rejected from
a cost-effectiveness perspective. When most simu-
lated ICERs fall into the lower right quadrant (Q4),
i.e. more health effect and lower costs, the interven-
tion (EMDR or PE) is said to show ‘dominance’ over
the control intervention (no treatment, WL).
Obviously this outcome is the best possible from an
economic perspective: the dominant treatment is
considered to be the preferred option over the no
treatment alternative. The bottom-left quadrant
(Q3) implies health loss but for concomitantly lower
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cost. For decision-making purposes we need to take
an additional step when the ICERs fall into the upper
right-hand quadrant (Q1) where better health is
obtained at additional costs. Then we need to address
the question about the willingness to pay (WTP) for
an additional unit of effect. We used a WTP ceiling of
€50,000 for gaining one extra QALY.
1.6. Sensitivity analysis
To assess the robustness of the main analysis we
carried out three sensitivity analyses. In the first two
we switched from EM imputation (used in the main
analysis) to last observation carried forward (LOCF)
and to regression imputation (REG) as alternatives.
The third re-analysis excluded the costs of admissions
to psychiatric hospitals from the EM imputed dataset,
as these were considered to be influential outlier costs
(i.e. only a few patients generated high hospitals
costs). Non-parametric paired samples Wilcoxon
testing was used to assess longer-term consolidation
of costs in PE and EMDR at 12-month follow-up.
2. Results
2.1. Sample
Table 1 presents the baseline characteristics of the inten-
tion-to-treat sample (N = 155). Regarding current symp-
toms at baseline, 61.9% of the participants had active
delusions, 40.0% had active hallucinations, 55.5% had
current core symptoms of schizophrenia, 60.6% reported
suicide attempts in the past and 45.2% had a current
medium to high suicidal risk (de Bont et al., 2016). At
baseline, there were no clinically or economically rele-
vant differences between the conditions. Treatment
dropout (EMDR 20%, PE 24.5%, p = .57) and dropout
from our main assessment at six-months follow-up
Table 1. Baseline characteristics of the intention-to-treat sample for the three conditions with costs under expectation
maximization imputation (N = 155).
EMDR
(n = 55)
PE
(n = 53)
WL
(n = 47)
Total sample
(n = 155)
Demographic characteristics
Age (years), mean (SD) 40.4 (11.3) 42.6 (10.3) 40.3 (9.7) 41.2 (10.5)
Female gender (%) 30 (54.5) 30 (56.6) 24 (51.1) 84 (54.2)
Dutch cultural background (%) 34 (61.8) 36 (67.9) 27 (57.4) 97 (62.6)
Lower educationa (%) 30 (54.5) 23 (43.4) 26 (55.3) 79 (51.0)
Unemployed (%) 51 (92.7) 45 (84.9) 41 (87.2) 137 (88.4)
Living alone or in sheltered housing (%) 36 (65.4) 34 (64.2) 30 (63.8) 100 (64.5)
Clinical characteristics
Psychosis, lifetime diagnosis MINI-Plus (%)
Schizophrenia 34 (61.8) 31 (58.5) 30 (63.8) 95 (61.3)
Schizoaffective disorder 15 (27.3) 17 (32.1) 13 (27.7) 45 (29.0)
Remaining psychotic disorders 3 (5.5) 1 (1.9) 1 (2.1) 5 (3.2)
Mood disorders with psychotic features 3 (5.4) 4 (7.6) 3 (6.4) 10 (6.4)
Chlorpromazine drug dose equivalentsb, mean (SD) 253.2 (250.5) 227.3 (187.9) 250.7 (232.8) 243.6 (224.2)
Psychosis duration in years, mean (SD) 18.2 (11.7) 18.9 (12.8) 15.7 (10.5) 17.7 (11.8)
PTSD, CAPS severity score, mean (SD) 72.1 (17.6) 69.6 (14.9) 68.1 (15.9) 69.9 (16.2)
PTSD duration in years, mean (SD) 21.1 (13.9) 22.8 (13.6) 18.95 (12.9) 21.0 (13.5)
Economic characteristics
Utility, EQ5D, Mean (SD) 0.55 (0.29) 0.46 (0.31) 0.43 (0.29) 0.48 (.30)
Costs, TiC-P, in 2014 Euro per month, Mean € (SD)
Health carec 689.2 (1005.5) 678.0 (747.2) 1012.6 (1699.8) 783.4 (1195.4)
Outpatient mental health service 262.4 (516.6) 261.0 (427.5) 260.0 (335.6) –
Inpatient mental health service 142.8 (746.2) 0 (0.0) 57.8 (249.0) –
Medical non-mental health care 16.4 (41.2) 21.7 (45.5) 14.8 (37.7) –
Family doctor/GP 16.2 (29.7) 27.4 (36.5) 19.0 (30.6) –
Alternative healing 0 (0.0) 9.8 (51.1) 1.5 (7.4) –
Psychopharmacologya 7.6 (8.9) 8.6 (12.9) 5.2 (5.9) –
Paramedical care 77.3 (159.8) 141.4 (253.6) 111.6 (257.0) –
Professional home care 45.6 (116.8) 63.8 (145.9) 43.1 (77.1) –
Informal care (family, friends) 103.2 (277.3) 120.2 (288.6) 477.2 (1629.7) –
Out-of-pocket costs (travel) 17.9 (22.2) 24.0 (22.5) 22.2 (21.3) –
Productivity losses 213.4 (318.5) 323.9 (600.9) 208.5 (315.6) 249.7 (436.1)
Work loss 5.7 (42.2) 34.1 (165.6) 42.9 (203.7) –
Work cut-back 21.8 (127.8) 118.2 (457.9) 51.4 (178.4) –
Domestic loss and cut-back 185.9 (292.5) 171.5 (206.1) 114.3 (116.1) –
Total societal cost 902.6 (1060.8) 1001.9 (905.4) 1221.1 (1717.6) 1033.1 (1252.9)
Abbreviations: CAPS = Clinician-Administered PTSD Scale; EMDR = eye movement desensitization and reprocessing; EQ5D = EuroQol 5D; MINI-Plus =
MINI-International Neuropsychiatric Interview-Plus; PE = Prolonged Exposure; PTSD = posttraumatic stress disorder; SD = standard deviation; TiC-P =
Trimbos and iMTA questionnaire on Costs associated with Psychiatric illness; WL = Waiting list.
a Lower = primary education or lower general secondary education, as opposed to intermediate to high vocational education or university.
b 100 mg CPZ = 2 mg Haldol; medication prescribed for psychotic disorders and mood disorders with psychotic features.
c The cost item of ‘outpatient mental health service’ included visits to psychiatrists, psychologists, nurses and so on. ‘General hospital’ included costs
related to somatic care visits. Visits to the ‘family doctor/GP’ were categorized separately. ‘Alternative healing’ included all visits to healthcare workers
outside regular care, e.g. paranormal healers. ‘Psychopharmacology’ included all medication plus dispensing costs of non-controlled-for medication.
‘Paramedical care’ included care such as physiotherapy or dietetics. ‘Professional home care’ included all professional household support whereas
‘informal care’ included all support from family and peers. Healthcare-related transportation costs (‘out-of-pocket costs’) included all trips to healthcare
services, including parking costs.
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(EMDR 22%, PE 15%, WL 15%, p = .56) also showed no
significant differences between the conditions.
2.2. Costs
The cost and effect outcomes of the main analysis are
presented in Table 2; note that the societal and
healthcare perspectives are included, and the produc-
tivity perspective can be deduced from this.
Compared to costs in the WL condition, healthcare
costs (i.e. costs of CAU plus the add-on experimental
intervention) were reduced by €1410 per patient in
the EMDR condition and by €501 per patient in the
PE condition. In other words, the experimental con-
ditions (EMDR and PE) were associated with lower
costs, even when offering EMDR or PE entails addi-
tional healthcare costs of their own. Compared to
costs in the WL condition, the total societal costs
(i.e. healthcare costs plus costs stemming from pro-
ductivity losses) were reduced by €1574 in the EMDR
condition and by €422 in the PE condition.
2.3. Effects
The main analysis showed that EMDR gained 0.052
more QALYs compared with WL: this is a significant
difference (robust SE = 0.025, t = 2.09, p = .039).
Similarly, PE gained 0.051 more QALYs compared
with WL (robust SE 0.024, t = 2.14, p = .035). In the
EMDR condition, 26%more patients fulfilled the criteria
of LoD than in the WL condition (incremental
LoD = 0.256, robust SE = 0.096, z = 2.66, p = .008).
Similarly, PE yielded an incremental effect of 22% (incre-
mental LoD = 0.223, robust SE 0.098, z = 2.28, p = .023).
2.4. Cost-utility analysis
2.4.1. Healthcare perspective
From the healthcare perspective, the ICUR of EMDR
was associated with a cost reduction of €26,924 per
QALY gained and in PE a reduction of €9741, i.e.
both PTSD treatment conditions are ‘dominant’ over
WL (i.e. comparatively, they yielded reduced health-
care costs while QALYs were gained).
2.4.2. Societal perspective
When adopting the societal perspective, compared to
WL, both EMDR and PE yielded lower costs while
gaining QALYs. The ICUR of EMDR is -€30,061 and
the ICUR in PE is -€8209. Therefore, both PTSD treat-
ment conditions seem to be the better choice, i.e. ‘domi-
nant’ over WL (i.e. better health outcomes for lower
costs). Figure 1 shows 2500 bootstrapped ICERs in
a scatterplot: for EMDR 97.4% and for PE 69.4% of
the ICERs fall into the ‘dominant’ quadrant (Q4). This
implies a high PE to very high EMDR probability that
the treatments are dominant over WL. Figure 1 also
shows the acceptability curves that depict the probabil-
ity that EMDR and PE are deemed cost-effective relative
to WL at varying willingness-to-pay ceilings for gaining
one QALY. The curves show that, if there is no will-
ingness to pay at all, EMDR still has a 98% probability
and PE about a 70% probability of being more cost-
effective than WL.
2.5. Cost-effectiveness analysis
2.5.1. Healthcare perspective
Comparison of WL and the experimental conditions
shows that the ICER of EMDR is -€5497 per LoD and
that of PE is -€2245, signifying that both experimen-
tal conditions are associated with better clinical out-
comes and lower healthcare costs.
2.5.2. Societal perspective
The ICER of EMDR is -€6138 and for PE is -€1892,
signifying lower costs for society while gaining one
additional LoD. Figure 2 presents the cost-
effectiveness graphs of LoD from the societal perspec-
tive. The scatter of the 2500 simulated ICERs shows
that 98.8 and 70.8% of the ICERs fall in the dominant
quadrant for EMDR and PE, respectively. When there
is no willingness to pay for a LoD, EMDR still has
a 99% probability and PE a 72% probability of being
cost-effective.
2.6. Sensitivity analyses
As shown in Table 2, all three sensitivity checks corro-
borated that EMDR and PE are dominant over WL in
terms of their cost-utility and cost-effectiveness. The
results of LOCF and REG imputed analyses are com-
parable to the main analysis, which was based on EM
imputation. An important finding is that one of the
sensitivity analyses, i.e. ‘EM analysis without psychia-
tric hospital costs’, showed smaller cost reductions than
the other three analyses, all of which included hospital
costs (main analysis, LOCF and REG analysis). This
finding indicates that a sizeable proportion of the rela-
tively lower costs in EMDR and PE originates from
fewer days in psychiatric hospitals.
2.7. Longer-term follow-up in EMDR and PE
Nonparametric paired samples Wilcoxon tests showed
a significant decrease between the follow-up at six
months and the extended follow-up at 12 months in
healthcare costs (z = −4.99, p < .001) and production
loss (z = −2.250, p = .024) in EMDR, whereas in PE the
healthcare costs (z = −5.794, p < .001) decreased and
productivity losses (z = −0.907, p = .364) remained the
same over time. Apparently, cost reductions in the
experimental conditions did not decay but were sus-
tained or even increased over time.
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2.8. Implementation costs
Up to now we have examined the so-called ‘steady-
state costs’ in our health economic evaluation, i.e. the
operating cost of offering CAU plus EMDR and PE
interventions. This was done to the exclusion of the
initial investment cost of about (i) €2800 for eight
days of EMDR and PE training, and (ii) an additional
€1100 for 10 sessions of supervision plus €1100 for 10
sessions of inter-vision. The sum total of these one-
off costs is €5000 per therapist. Assuming that
a trained and supervised therapist treats 10 patients
in the first implementation year, then the per-patient
costs would average at 5000/10 = €500; in the present
study, these are costs recouped within six months by
offering PTSD treatment. Therefore, the implementa-
tion costs can be seen as a good return on investment.
Obviously, the per-patient costs of the implementa-
tion decrease after the initial phase, although some
costs for supervision and/or inter-vision might
continue.
3. Discussion
3.1. Main findings
This study evaluated the cost-effectiveness of
EMDR and PE therapy for treating PTSD in
patients with a psychotic disorder compared to
CAU for these patients while in WL for PTSD
treatment. Costs and effects were measured at six-
months follow-up. Convincing evidence was
obtained that both EMDR and PE are likely to
reduce costs and yield better outcomes with regard
to health gains expressed in QALYs and PTSD
‘Loss of diagnosis’. Three sensitivity analyses con-
firmed the robustness of the main findings. One
sensitivity analysis provided an indication that, to
some extent, lower costs in PTSD treatment origi-
nated from fewer days of hospital admission.
A longer-term (12-month) assessment of costs in
the treatment conditions showed that cost reduc-
tions were sustained or even increased.
EMDR vs WL: societal costs and QALY gain PE vs WL: societal costs and QALY gain.
EMDR vs WL: cost-utility acceptability curve and QALY PE vs WL: cost-utility acceptability curve and QALY
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Figure 1. Cost-utility of QALY gain in main analysis (EM) after bootstrapping (n = 2500) comparing EMDR and PE to WL: ICUR
planes and acceptability curves.
Abbreviations: CAU = care as usual; EMDR = eye movement desensitization and reprocessing; ICUR = incremental cost-utility ratio; PE =
prolonged exposure; QALY = Quality Adjusted Life Year; Q1 = Quadrant 1 (more effective, more expensive); Q2 = Quadrant 2 (the inferior
quadrant: less effective, more expensive); Q3 = Quadrant 3 (less effective, less expensive); Q4 = Quadrant 4 (the dominant quadrant: more
effective, less expensive); WL = waiting list.
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3.2. Strengths and limitations
3.2.1. Strengths
To our knowledge, this is the first study to evaluate
the cost-effectiveness of guideline trauma-focused
treatment protocols for PTSD in psychotic psychia-
tric patients. Additionally, this study is the first to
examine the cost-effectiveness of EMDR therapy in
any patient group. The training and implementation
of the treatments we studies is considered feasible in
clinical practice, since EMDR and PE protocols are
widely used and easily accessible. Dropout was low
and comparable to PTSD studies in other patient
groups (Hembree et al., 2003).
3.2.2. Limitations
A six-month follow-up is too short to draw final con-
clusions, as differences in costs and effects between the
conditions might change over time. However, we
found favourable developments in the costs at the
extended 12-month follow-up concomitant with pre-
viously reported beneficial effects at 12-month follow-
up on PTSD, depression, paranoid-referential thinking
and remission from schizophrenia (van Den Berg
et al., 2018) and a strongly reduced re-victimization
risk (van Den Berg et al., 2015a). This suggests that
cost reductions could increase further over time.
Another limitation is that the economic evaluation
relied on participants’ self-report regarding healthcare
usage and changes in productivity; however,
a validation study found a satisfactory to nearly perfect
agreement between patient-reported data and data
provided by health services (Bouwmans et al., 2013).
Third, the imputation of missing endpoints using the
EM algorithm might have added to outcome uncer-
tainty; however, all of our sensitivity analyses repli-
cated the results of the main analysis. Finally, the
generalizability of our results is limited due to differ-
ences in healthcare systems across settings and coun-
tries. We recommend replication in different mental
healthcare settings.
4. Conclusions
The present results suggest that in individuals with
psychotic disorders and PTSD add-on EMDR and PE
EMDR vs WL: Societal costs and Loss of Diagnosis PE vs WL: Societal costs and Loss of Diagnosis
EMDR vs WL: cost-utility acceptability curve and Loss of Diagnosis PE vs WL: cost-utility acceptability curve and Loss of Diagnosis
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Figure 2. Cost-effectiveness of PTSD loss of diagnosisa in main analysis (EM) after bootstrapping (n = 2500) comparing EMDR
and PE to WL: ICER planes and acceptability curves.
Abbreviations: CAU = care as usual; EMDR = eye movement desensitization and reprocessing; ICER = incremental cost-effectiveness ratio; PE =
prolonged exposure; PTSD = posttraumatic stress disorder; QALY = Quality Adjusted Life Year; Q1 = Quadrant 1 (more effective, more
expensive); Q2 = Quadrant 2 (the inferior quadrant: less effective, more expensive); Q3 = Quadrant 3 (less effective, less expensive); Q4 =
Quadrant 4 (the dominant quadrant: more effective, less expensive).a ‘PTSD loss of diagnosis’ indicates the combination of no longer meeting
CAPS IV-PTSD criteria + CAPS IV-severity score < 45.
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for PTSD reduce costs and yield better quality of life
(more QALY gains) and clinical effects (more loss of
diagnosis) than standard treatment for psychosis
alone. At every level of society’s willingness to pay
for a unit health gain (one loss of diagnosis, one
QALY gained), adding PTSD treatment is the pre-
ferred option. The current findings challenge the ‘no
trauma-focused treatment’ paradigm for psychotic
individuals. Adjustment of clinical treatment guide-
lines and implementation decisions seem warranted.
With about one in eight patients with a psychotic
disorder having PTSD, implementing PTSD treat-
ment might yield considerable personal and eco-
nomic benefits in this relatively costly sector within
mental health care.
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